Source: harmony and beauty

When the performance turned into a loss, senior executives were involved in short-term trading and illegally bought and sold the company's shares.

After trading on May 21, Lanwei Medical issued an announcement that Mao Zhisen, director and deputy general manager of the company, traded short-term and illegally traded shares of the company. On the same day, the Shanghai Bureau of the CSRC issued a warning letter to it.

The deputy general manager bought the company's stock the day after the daily limit.

According to the announcement, Mao Zhisen, director and deputy general manager of Lanwei Medical, did not hold shares in the company and bought and sold shares of the company from March 21 to March 26, 2024, and he did not inform the company of the reduction plan in advance for pre-disclosure.

On March 21, Mao Zhisen bought a total of 16300 shares of the company through centralized bidding, with a total transaction value of 23.JokermegawaysslotThe average transaction price was 14.54 yuan per share, while the highest price of the day was 14.77 yuan and the closing price was 14.05 yuan.

On March 26th, Mao Zhisen sold his shares twice with a transaction value of 106300 yuan. According to the first-in-first-out principle, Mao Zhisen's short-term trading gain is a loss of 23600 yuan and a principal loss.Jokermegawaysslot10%.

It is worth mentioning that on the trading day before Mao Zhisen bought the stock, Lanwei Medical's share price rose by the limit, closing at 13.48 yuan. Since the year's low of 7.34 yuan set on February 6, the stock price has risen by 83.65% for more than a month. The share price closed up another 4.05% on March 21, but fell 5.69% in the next two trading days, 8.91% in the following two trading days, and 1.57% on March 26, down more than 15% in just three trading days.

Lanwei Medical said that this short-term trading, illegal reduction, there is no case of trading the company's shares because of inside information, nor the use of insider information to seek profits.

On the same day, the Shanghai Bureau of the CSRC issued the "decision on taking measures to issue a warning letter against Mao Zhisen" (Shanghai Securities Supervisory decision (2024) No. 223), taking administrative supervision measures to issue a warning letter to him.

According to the data, Mao Zhisen has worked in the company since October 2019 and is now a director and deputy general manager of the company. In 2023, Mao Zhisen will earn 962500 yuan a year before tax.

The performance turned into a loss after the end of the dividend.

Lanwei Medicine mainly provides overall solutions for the medical diagnosis industry, the main business includes in vitro diagnosis product sales, medical diagnosis services.

At the beginning of listing, Lanwei Medical revenue mainly comes from the sales of in vitro diagnostic products. In 2021, the business accounted for 61.58% of revenue.

Subsequently, due to the change of the objective environment, the revenue of medical diagnostic services increased compared with the same period last year, and the proportion of revenue also increased. In 2022, the business income increased to 3.259 billion yuan from 947 million yuan in the previous year, and the proportion of revenue also increased to 53.26%.

In 2023, Lanwei Medical's performance took a sharp turn for the worse, with revenue falling 60.13% to 1.674 billion yuan compared with the same period last year, and net profit changing from 617 million yuan last year to 142 million yuan.

Lanwei Medical explained that due to the reduced demand for testing, the business income of medical diagnostic services declined greatly, resulting in a decline in the company's net profit.

In addition, it is worth noting that as most of the downstream customers are hospitals and other medical institutions, the company's accounts receivable reached 1.01 billion yuan, up from 2.223 billion yuan last year. Lanwei Medical hints on this, if the company fails to continue to strengthen the management of accounts receivable, it will still face the risk of bad debts due to difficult collection of accounts receivable.